Abstract
Background Tuberculosis (TB) and lung cancer (LC) are major respiratory diseases causing significant deaths worldwide. Both primarily affect the lungs and share similar clinical symptoms. The comorbidity rate between TB and LC is high, and epidemiological data suggest a potential association between the two diseases. However, the detailed causal relationships and potential mediators remain underexplored due to limited evidence from observational studies. This study aims to elucidate the relationship between TB and LC, including the pathological subtypes of LC, and to investigate the potential mediating effects of immune cells.
Materials and Methods The genetic variants for TB and LC were sourced from the IEU Open GWAS Project, while the data for the 731 immunocyte phenotypes were obtained from their genome-wide association studies (GWAS). The inverse variance-weighted (IVW), MR-Egger, weighted median, simple mode and weighted mode were used to evaluate the causal relationship between TB and LC. We then applied a two-step Mendelian randomization (MR) analysis to examine the roles of immunocyte phenotypes as mediators. Additionally, multiple sensitivity analyses were conducted to ensure the reliability of the MR results.
Results The results of the IVW methods of the MR analysis indicated a causal relationship between TB and LC, demonstrating a positive correlation (OR = 1.072, 95% CI: 1.010–1.137, P < 0.05). The immune phenotype CD4 on CD39+ resting regulatory T cell is implicated in the linkage between TB and LC as well (mediation proportion: 9.09%). Additionally, no evidence was found to support a reverse causal relationship between TB and LC, nor a causal relationship between TB and the pathological subtypes of LC. There was no observed heterogeneity or horizontal pleiotropy in our MR results.
Conclusion Our study suggests the causal effect of TB on increased LC risk, with immune phenotype playing a mediating role. These insights provide a significant basis for the prevention and concurrent management of LC and TB.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Natural Science Foundation of China (32394014, 82304575), Guangdong Provincial Basic and Applied Basic Research Fund (2022A1515110883).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IEU Open GWAS Project (https://gwas.mrcieu.ac.uk/) GWAS Catalog (https://www.ebi.ac.uk/gwas/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
